U.S. Markets closed

Four Healthcare Stocks Seeing Gains On Wednesday

CORAL GABLES, FL / ACCESSWIRE / March 6, 2019 / When considering the future of the healthcare stock market, it's important to understand that the market is built upon an industry purposed with creating innovative means for people to feel healthy. At the end of the day, our health is our key priority, and it is the responsibility of the healthcare industry to meet the growing demands of consumers as more diseases are discovered. Interestingly enough, amid this responsibly lies the opportunity for healthcare companies to unlock lucrative potential and attract investors to the space. If companies in the healthcare sector continue to take creative approaches to design drug treatments and care solutions, this will, in turn, improve the lives of consumers, thus catalyzing significant investor interest in the sector. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Novavax Inc (NVAX), Valeritas Holdings Inc (NASDAQ:VLRX), and Aytu BioScience Inc (NASDAQ:AYTU) represent 4 healthcare companies worth paying attention to on Wednesday.

Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company stopping at nothing to ensure they are developing innovative approaches that combine human skill-based expertise with state-of-the-art technologies to create a patient-centric healthcare framework.

Premier Health Group (OTC:PHGRF) (CSE:PHGI) today announced that the Company is working with NexTech AR Solutions to explore bringing augmented reality technologies to its patient-centric healthcare app. Premier Health will be working with NexTech to develop educational tools for healthcare professionals and patients alike – some of which will be created and commercialized content for third parties. Utilizing AR as a learning tool in training healthcare professionals creates a highly engaging and immersive educational experience which aids in retention and how well complex concepts can be grasped.

In addition to their collaborative efforts, the companies will investigate possible AR treatment delivery options. For example, in relation to physiotherapy, digital demonstrations can be mapped directly onto the movements patients perform as part of their recovery.

Following the announcement, Dr. Essam Hamza, CEO of Premier Health Group (OTC:PHGRF) (CSE:PHGI), stated, ''at Premier Health we pride ourselves in being at the forefront of changes in healthcare, so we are thrilled to be a part of the future of healthcare by enabling state of the art technological advancements to our patient-centric telemedicine app. AR has the potential to revolutionize both the access to data and the delivery of healthcare. The technology will help doctors and patients alike – doctors will have access to the latest and most relevant information about their patients while patients can use AR for self-education and improving the quality of treatment they receive.''

For More Information On Premier Health Group, Click Here

Novavax Inc (NVAX) announced towards the end of February results from Prepare™, a global Phase 3 clinical trial using ResVax, an aluminum adjuvanted respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine. ResVax is being developed to protect infants via maternal immunization against RSV disease.

Stanley Erck, President, and CEO of Novavax commented, ''the potential to prevent these most serious outcomes during infants' most vulnerable months of life could have a profound impact upon the global burden of RSV disease. Our next steps include meeting with U.S. and European regulators to review these data and to discuss the path forward for licensure. We wish to acknowledge and thank the investigators, the Novavax team and the many mothers and their families around the world that participated in this historic trial, bringing the world one step closer to an RSV vaccine.''

For More Information On Novavax Inc, Click Here

Valeritas Holdings Inc (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, announced earlier this week financial results for the three months and full year ended December 31, 2018. Per the details of their results, Revenues in the fourth quarter grew 19% year-over-year to $6.9 million from $5.8 million in the fourth quarter of 2017 and grew 30% to $26.4 million for the full year ended December 31, 2018, from $20.2 million for the full year 2017.

Following the announcement, John Timberlake, President, and CEO of Valeritas said, ''importantly, additional studies continue to demonstrate that use of V-Go provides significant clinical and economic benefits compared to conventional insulin injection delivery in patients with Type 2 diabetes. With the just-completed expansion of our U.S. sales force by twenty-five territories, we look forward to building on our momentum of strong execution, and we remain confident in our ability to drive solid sales volume and patient market share in 2019."

For More Information on Valeritas Holdings Inc, Click Here

Aytu BioScience Inc (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address patient needs, today announced the Company's licensing agreement with SUDA Pharmaceuticals Ltd to distribute ZolpiMist™ (zolpidem tartrate oral spray) outside the United States and Canada. ZolpiMist is a rapidly acting oral spray sleep aid and is the only FDA-approved oral spray formulation of zolpidem tartrate. Zolpidem tartrate tablets are marketed in the U.S. under the brand name Ambien®.

John Disbrow, CEO of Aytu BioSciences, stated, ''we are pleased to be partnering with SUDA as they develop ZolpiMist commercial opportunities around the world. In a short period of time, the SUDA team has entered into several sublicensing arrangements with prominent pharmaceutical companies. As such, we expect to see regulatory clearance in at least one market in the coming year.''

For More Information On Aytu BioScience Inc, Click Here

What Is Stock Price (StockPrice.com)?

Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.

StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.

At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC (owners of MarijuanaStocks.com), MIDAM VENTURES, LLC and Premier Health Group Inc. Midam was hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 CASH for & were paid ''500,000'' shares of restricted common shares (as of 1/2/2019). Midam has been compensated an additional $100,000 by Premier Health Group to extend the period of coverage to May 1, 2019. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the ''500,000'' shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.

Contact Information:


SOURCE: StockPrice.com

View source version on accesswire.com: